Open-label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2-, Locally Advanced or Metastatic Breast Cancer with an ESR1 Mutation.